CA2344623A1 - Method to determine a predisposition to leptin treatment - Google Patents

Method to determine a predisposition to leptin treatment Download PDF

Info

Publication number
CA2344623A1
CA2344623A1 CA002344623A CA2344623A CA2344623A1 CA 2344623 A1 CA2344623 A1 CA 2344623A1 CA 002344623 A CA002344623 A CA 002344623A CA 2344623 A CA2344623 A CA 2344623A CA 2344623 A1 CA2344623 A1 CA 2344623A1
Authority
CA
Canada
Prior art keywords
leptin
obese
individual
level
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002344623A
Other languages
English (en)
French (fr)
Inventor
Mark A. Mccamish
Pamela Hunt
John A. Lubina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2344623A1 publication Critical patent/CA2344623A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002344623A 1998-10-02 1999-09-21 Method to determine a predisposition to leptin treatment Abandoned CA2344623A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16545398A 1998-10-02 1998-10-02
US18183698A 1998-10-27 1998-10-27
US09/165,453 1998-10-27
US09/181,836 1998-10-27
PCT/US1999/021903 WO2000020872A1 (en) 1998-10-02 1999-09-21 Method to determine a predisposition to leptin treatment

Publications (1)

Publication Number Publication Date
CA2344623A1 true CA2344623A1 (en) 2000-04-13

Family

ID=26861401

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002344623A Abandoned CA2344623A1 (en) 1998-10-02 1999-09-21 Method to determine a predisposition to leptin treatment

Country Status (5)

Country Link
EP (1) EP1118001A1 (ja)
JP (1) JP2002526780A (ja)
AU (1) AU6396999A (ja)
CA (1) CA2344623A1 (ja)
WO (1) WO2000020872A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1444516T3 (da) 2001-10-22 2010-11-15 Amgen Inc Anvendelse af leptin til behandling af lipoatrofi hos mennesker og fremgangsmåde til at bestemme en prædisposition for denne behandling
ES2325773T5 (es) 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
CA2723833A1 (en) 2008-05-12 2009-11-19 Umut Ozcan Methods and compositions for the treatment of obesity
EP2326339A4 (en) 2008-05-21 2012-06-20 Neurotez Inc METHOD FOR TREATING PROGRESSIVE COGNITIVE DISORDER IN CONNECTION WITH NEUROFIBRILLARY TANGLES
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
EP2352510A4 (en) 2008-11-04 2012-08-29 Neurotez Inc LEPTIN COMPOSITIONS AND METHODS OF TREATING PROGRESSIVE COGNITIVE DISORDERS DUE TO THE ASSEMBLY OF NEUROFIBRILLARY BUNNELS AND AMYLOID BETA
ES2630031T3 (es) 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
LT2900230T (lt) 2012-09-27 2019-01-10 The Children`S Medical Center Corporation Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai
TR201901299T4 (tr) 2013-11-26 2019-02-21 Childrens Medical Ct Corp Obezite tedavisine yönelik bileşikler ve bunların kullanım yöntemleri.
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
PT3509624T (pt) 2016-09-12 2023-08-28 Amryt Pharmaceuticals Inc Métodos de deteção de anticorpos neutralizantes anti-leptina
WO2019032469A1 (en) * 2017-08-07 2019-02-14 Aegerion Pharmaceuticals, Inc. TREATMENT OF OVERWEIGHT AND OBESITY ASSOCIATED WITH LEPTIN IMPAIRMENT

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0836479A2 (en) * 1995-06-30 1998-04-22 Eli Lilly And Company Methods for treating diabetes

Also Published As

Publication number Publication date
WO2000020872A1 (en) 2000-04-13
AU6396999A (en) 2000-04-26
EP1118001A1 (en) 2001-07-25
JP2002526780A (ja) 2002-08-20

Similar Documents

Publication Publication Date Title
EP1285664B1 (en) Methods of increasing lean tissue mass using OB protein compositions
Geldszus et al. Serum leptin and weight reduction in female obesity
Horn et al. Radioimmunoassay for the detection of leptin in human serum
EP2066174B1 (en) Compositions containing alpha-1-antitrypsin and methods for use
WO2006078463A2 (en) Method for treating cardiovascular disease
US7718400B2 (en) Methods of increasing lean tissue mass using OB protein compositions
US20180333464A1 (en) Methods of using interleukin-10 for treating diseases and disorders
CA2344623A1 (en) Method to determine a predisposition to leptin treatment
US9550821B2 (en) Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin
EP1701978B1 (en) Use of soluble T-Cadherin for the treatment of metabolic disorders
Karnieli et al. Regulation of glucose transporters in diabetes
EP0580752A1 (en) Human bone derived insulin like growth factor binding protein
WO2005020898A2 (en) Methods of reducing visceral fat by increasing levels of insulin-like growth factor-i (igf-i)
MXPA01003285A (ja)
JP4044842B2 (ja) 肥満を処置し得る薬剤のスクリーニング法
US20100120682A1 (en) Compositions for increasing body weight, use and methods
RU2794170C2 (ru) ЛЕЧЕНИЕ АНОМАЛЬНОГО ОТЛОЖЕНИЯ ВИСЦЕРАЛЬНОГО ЖИРА С ИСПОЛЬЗОВАНИЕМ РАСТВОРИМЫХ ПОЛИПЕПТИДОВ РЕЦЕПТОРА ФАКТОРА РОСТА ФИБРОБЛАСТОВ 3 (sFGFR3)
CN117881416A (zh) 用于治疗儿童的骨骼发育不良的c型利钠肽变体
EP1705256A1 (en) Methods for the treatment of insulin resistance and disease states characterized by insulin resistance
AU759025B2 (en) Use of growth hormone
Zoico et al. Leptin physiology and pathophysiology in the elderly
JP2008507559A (ja) ２０ｋＤａ胎盤成長ホルモン変種を使用した糖尿病非誘発性療法
AU2004200516A1 (en) Methods of Increasing Lean Tissue Mass Using OB Protein Compositions

Legal Events

Date Code Title Description
FZDE Discontinued